OR WAIT null SECS
Accurately targeted immunotherapies through reliable neoantigen recognition enable personalized medicine development.
Activation and expansion are essential for success in both autologous and allogeneic therapies.
Continuous manufacturing and a quality-by-design development approach are a natural fit.
October 10, 2023
Orakl Oncology has raised funds to develop its precision oncology platform and accelerate drug development.
October 09, 2023
Eli Lilly and Company has received a complete response letter from FDA for its anti-dermatitis biologic therapeutic, lebrikizumab.
Sanofi is set to pay $175 million upfront to Janssen, followed by development and commercial milestones.
Webinar Date/Time: Thu, Oct 26, 2023 11:00 AM EDT
October 05, 2023
Clene was awarded the four-year grant for the National Institute of Neurological Disorders and Stroke to support an Expanded Access Protocol for ALS drug.
The program will allow sponsors of certain CBER and/or CDER-regulated products more frequent communication with FDA staff.
October 04, 2023
The prize was awarded jointly to Katalin Karikó and Drew Weissman for their groundbreaking discovery regarding modification of the bases in mRNA.
Pfizer has entered into a collaboration with Ginkgo Bioworks to discover novel RNA molecules across priority research areas.
October 02, 2023
Government provides a spoonful of sugar, and genuine leadership, for good medicines.
Webinar Date/Time: Tuesday, October 17, 2023 at 11am EDT | 4pm BST | 5pm CEST